WO2010089775A3 - Forme galénique améliorée de médicament destiné à administrer de manière contrôlée un ou plusieurs agents pharmaceutiquement actifs - Google Patents

Forme galénique améliorée de médicament destiné à administrer de manière contrôlée un ou plusieurs agents pharmaceutiquement actifs Download PDF

Info

Publication number
WO2010089775A3
WO2010089775A3 PCT/IN2010/000058 IN2010000058W WO2010089775A3 WO 2010089775 A3 WO2010089775 A3 WO 2010089775A3 IN 2010000058 W IN2010000058 W IN 2010000058W WO 2010089775 A3 WO2010089775 A3 WO 2010089775A3
Authority
WO
WIPO (PCT)
Prior art keywords
active agent
dosage form
controlled delivery
improved drug
pharmaceutically active
Prior art date
Application number
PCT/IN2010/000058
Other languages
English (en)
Other versions
WO2010089775A2 (fr
Inventor
Atul Patil
Anil Kadam
Anandi Krishnan
Sameer Paigankar
Original Assignee
Getz Pharma Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Getz Pharma Research filed Critical Getz Pharma Research
Publication of WO2010089775A2 publication Critical patent/WO2010089775A2/fr
Publication of WO2010089775A3 publication Critical patent/WO2010089775A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un système amélioré d'administration de médicament destiné à administrer de manière contrôlée un ou plusieurs agents pharmaceutiquement actifs en utilisant une association de polymères hydrophobes et hydrophiles dans un noyau interne et une couche de revêtement d'une forme galénique. L'invention utilise un rapport spécifique d'éthyl cellulose et d'hydroxypropyl méthylcellulose pour obtenir la libération souhaitée de l'agent actif.
PCT/IN2010/000058 2009-02-05 2010-02-03 Forme galénique améliorée de médicament destiné à administrer de manière contrôlée un ou plusieurs agents pharmaceutiquement actifs WO2010089775A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN230MU2009 2009-02-05
IN230MUM/2009 2009-02-05
IN173/MUM2010 2010-01-22
IN173MU2010 2010-01-22

Publications (2)

Publication Number Publication Date
WO2010089775A2 WO2010089775A2 (fr) 2010-08-12
WO2010089775A3 true WO2010089775A3 (fr) 2011-06-23

Family

ID=42307224

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000058 WO2010089775A2 (fr) 2009-02-05 2010-02-03 Forme galénique améliorée de médicament destiné à administrer de manière contrôlée un ou plusieurs agents pharmaceutiquement actifs

Country Status (1)

Country Link
WO (1) WO2010089775A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1008842B (el) * 2015-08-06 2016-09-05 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα περιεχον εναν ατυπο αντιψυχωσιμο παραγοντα και μεθοδος για την παρασκευη αυτου
US20190105277A1 (en) * 2016-04-05 2019-04-11 Pharmathen S.A. Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
CN115531339B (zh) * 2022-11-24 2023-03-17 山东则正医药技术有限公司 一种帕利哌酮缓释片及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1473030A1 (fr) * 2003-05-02 2004-11-03 Dexcel Ltd. Formulation de comprimé à libération prolongée du venlafaxine
WO2006017537A1 (fr) * 2004-08-04 2006-02-16 Alza Corporation Composition de libération soutenue de médicament manifestant un schéma de libération d’ordre croissant nul, procédés de fabrication d’une telle composition
WO2007044234A1 (fr) * 2005-10-07 2007-04-19 Alza Corporation Forme posologique osmotique a aspects de liberation controlee et de liberation rapide
WO2009025859A1 (fr) * 2007-08-21 2009-02-26 Teva Pharmaceutical Industries Ltd. Formulation à libération prolongée de palipéridone

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1473030A1 (fr) * 2003-05-02 2004-11-03 Dexcel Ltd. Formulation de comprimé à libération prolongée du venlafaxine
WO2006017537A1 (fr) * 2004-08-04 2006-02-16 Alza Corporation Composition de libération soutenue de médicament manifestant un schéma de libération d’ordre croissant nul, procédés de fabrication d’une telle composition
WO2007044234A1 (fr) * 2005-10-07 2007-04-19 Alza Corporation Forme posologique osmotique a aspects de liberation controlee et de liberation rapide
WO2009025859A1 (fr) * 2007-08-21 2009-02-26 Teva Pharmaceutical Industries Ltd. Formulation à libération prolongée de palipéridone

Also Published As

Publication number Publication date
WO2010089775A2 (fr) 2010-08-12

Similar Documents

Publication Publication Date Title
WO2010111232A3 (fr) Dispositif médical d'administration de médicament
WO2012009684A3 (fr) Dispositif médical d'administration de médicament
WO2007133583A3 (fr) Formes posologiques solides à libération modifiée d'ordre zéro
WO2008022932A3 (fr) Système de libération contrôlée et procédé de préparation correspondant
WO2007103557A3 (fr) Revêtement de capsules avec des ingrédients pharmaceutiques actifs
CY2019021I1 (el) Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων
WO2009104175A3 (fr) Utilisation de microtubes électrofilés pour l'administration de médicaments
WO2011084618A3 (fr) Compositions et procédés d'administration de médicaments par voie orale
WO2011107855A3 (fr) Forme dosifiée sous forme de suspension liquide à libération prolongée pour une administration par voie orale
WO2009088414A3 (fr) Formes posologiques pharmaceutiques orales
WO2011112229A3 (fr) Préparations d'agent thérapeutique pour une administration dans une lumière du tractus intestinal à l'aide d'un dispositif d'administration de médicament avalable
MY163892A (en) Drug delivery system
WO2006026187A3 (fr) Endoprothese pourvues de revetements a elution de medicaments
WO2006103661A3 (fr) Absorption regulee de statines dans l'intestin
WO2010037854A3 (fr) Forme pharmaceutique orale a base de microgranules a liberation prolongee resistante a l' alcool
WO2006054307A3 (fr) Absorption maitrisee de statines dans l'intestin
WO2009099935A3 (fr) Dispositifs médicaux recouverts de médicament pour une libération différentielle de médicament
NZ594311A (en) Pharmaceutical composition comprising tamsulosin and solifenacin for oral administration
WO2011080141A3 (fr) Implant s'éliminant par dégradation pour la libération prolongée d'un principe actif
MX2009008197A (es) Forma de dosificacion de liberacion extendida.
HRP20181517T1 (hr) Sustav dostave lijeka za administraciju u vodi topljive, kationske i amfifilne farmaceutski aktivne tvari
TN2011000307A1 (en) Galenic formulation of organic compounds
WO2010089775A3 (fr) Forme galénique améliorée de médicament destiné à administrer de manière contrôlée un ou plusieurs agents pharmaceutiquement actifs
EP2231192A4 (fr) Système d'administration de médicament pour administrer une substance pharmaceutiquement active amphiphile, cationique et hydrosoluble
WO2011103920A3 (fr) Formule pharmaceutique ou nutraceutique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10719786

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 31-01-2012)

122 Ep: pct application non-entry in european phase

Ref document number: 10719786

Country of ref document: EP

Kind code of ref document: A2